This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cleary, J. D.
Right arrow Articles by Perlin, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cleary, J. D.
Right arrow Articles by Perlin, D. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2008, p. 2263-2265, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.01568-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment{triangledown}

John D. Cleary,1* Guillermo Garcia-Effron,2 Stanley W. Chapman,1 and David S. Perlin2

Mycotic Research Center, University of Mississippi Schools of Pharmacy and Medicine, Jackson, Mississippi,1 Public Health Research Institute, UMDNJ-New Jersey Medical School, Newark, New Jersey2

Received 5 December 2007/ Returned for modification 20 January 2008/ Accepted 22 March 2008

We describe a case of recurring Candida glabrata infection in a 68-year-old African-American female on caspofungin therapy. The initial isolate was susceptible, but isolates recovered during following relapses were not. All isolates were clonal, and high-MIC strains contained a mutation in the highly conserved hot spot 1 region of Fks1p.


* Corresponding author. Mailing address: Departments of Pharmacy Practice & Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MI 39216. Phone: (601) 984-2617. Fax: (601) 984-2618. E-mail: Jcleary{at}medicine.umsmed.edu

{triangledown} Published ahead of print on 31 March 2008.


Antimicrobial Agents and Chemotherapy, June 2008, p. 2263-2265, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.01568-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Katiyar, S. K., Edlind, T. D. (2009). Role for Fks1 in the Intrinsic Echinocandin Resistance of Fusarium solani as Evidenced by Hybrid Expression in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 53: 1772-1778 [Abstract] [Full Text]  
  • Garcia-Effron, G., Park, S., Perlin, D. S. (2009). Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints. Antimicrob. Agents Chemother. 53: 112-122 [Abstract] [Full Text]  
  • Garcia-Effron, G., Kontoyiannis, D. P., Lewis, R. E., Perlin, D. S. (2008). Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic Malignancies. Antimicrob. Agents Chemother. 52: 4181-4183 [Abstract] [Full Text]  
  • Thompson, G. R. III, Wiederhold, N. P., Vallor, A. C., Villareal, N. C., Lewis, J. S. II, Patterson, T. F. (2008). Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection. Antimicrob. Agents Chemother. 52: 3783-3785 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., Sheehan, D. J., Walsh, T. J. (2008). Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints. J. Clin. Microbiol. 46: 2620-2629 [Abstract] [Full Text]